These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 22675142)

  • 21. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Allopurinol efficacy in patients with tophus gout and chronic renal failure].
    Iakunina IA; Barskova VG; Nasonova VA
    Ter Arkh; 2006; 78(6):88-91. PubMed ID: 16881370
    [No Abstract]   [Full Text] [Related]  

  • 23. A case of naturally evolving gout in an elderly man.
    Bolzetta F; Veronese N; Mosele M; Sergi G; Manzato E; Giantin V
    Arch Gerontol Geriatr; 2012; 55(2):497-8. PubMed ID: 21944427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gout in ambulatory care settings in the United States.
    Krishnan E; Lienesch D; Kwoh CK
    J Rheumatol; 2008 Mar; 35(3):498-501. PubMed ID: 18260174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tophaceous joint disease strongly predicts hand function in patients with gout.
    Dalbeth N; Collis J; Gregory K; Clark B; Robinson E; McQueen FM
    Rheumatology (Oxford); 2007 Dec; 46(12):1804-7. PubMed ID: 17982165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.
    Mockenhaupt M; Viboud C; Dunant A; Naldi L; Halevy S; Bouwes Bavinck JN; Sidoroff A; Schneck J; Roujeau JC; Flahault A
    J Invest Dermatol; 2008 Jan; 128(1):35-44. PubMed ID: 17805350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
    Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM
    Clin Pharmacokinet; 2007; 46(8):623-44. PubMed ID: 17655371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
    Sarawate CA; Brewer KK; Yang W; Patel PA; Schumacher HR; Saag KG; Bakst AW
    Mayo Clin Proc; 2006 Jul; 81(7):925-34. PubMed ID: 16835972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
    Zhang W; Doherty M; Bardin T; Pascual E; Barskova V; Conaghan P; Gerster J; Jacobs J; Leeb B; Lioté F; McCarthy G; Netter P; Nuki G; Perez-Ruiz F; Pignone A; Pimentão J; Punzi L; Roddy E; Uhlig T; Zimmermann-Gòrska I;
    Ann Rheum Dis; 2006 Oct; 65(10):1312-24. PubMed ID: 16707532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).
    Mikuls TR; Farrar JT; Bilker WB; Fernandes S; Saag KG
    Rheumatology (Oxford); 2005 Aug; 44(8):1038-42. PubMed ID: 15870145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.
    Hung SI; Chung WH; Liou LB; Chu CC; Lin M; Huang HP; Lin YL; Lan JL; Yang LC; Hong HS; Chen MJ; Lai PC; Wu MS; Chu CY; Wang KH; Chen CH; Fann CS; Wu JY; Chen YT
    Proc Natl Acad Sci U S A; 2005 Mar; 102(11):4134-9. PubMed ID: 15743917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.
    Riedel AA; Nelson M; Joseph-Ridge N; Wallace K; MacDonald P; Becker M
    J Rheumatol; 2004 Aug; 31(8):1575-81. PubMed ID: 15290738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. THE USE OF ALLOPURINOL (HPP) TO CONTROL HYPERURICEMIA IN PATIENTS ON CHRONIC INTERMITTENT HEMODIALYSIS.
    HAYES CP; METZ EN; ROBINSON RR; RUNDLES RW
    Trans Am Soc Artif Intern Organs; 1965; 11():247-54. PubMed ID: 14329092
    [No Abstract]   [Full Text] [Related]  

  • 34. Allopurinol hypersensitivity syndrome: a review.
    Arellano F; Sacristán JA
    Ann Pharmacother; 1993 Mar; 27(3):337-43. PubMed ID: 8453174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs?
    Kot TV; Day RO; Brooks PM
    Med J Aust; 1993 Aug; 159(3):182-4. PubMed ID: 8336619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cell-mediated immunity in allopurinol-induced hypersensitivity.
    Braden GL; Warzynski MJ; Golightly M; Ballow M
    Clin Immunol Immunopathol; 1994 Feb; 70(2):145-51. PubMed ID: 8299230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.
    Hande KR; Noone RM; Stone WJ
    Am J Med; 1984 Jan; 76(1):47-56. PubMed ID: 6691361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma oxipurinol concentrations during allopurinol therapy.
    Emmerson BT; Gordon RB; Cross M; Thomson DB
    Br J Rheumatol; 1987 Dec; 26(6):445-9. PubMed ID: 3690140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial: An evaluation of the pathogenesis of gouty kidney.
    Emmerson BT; Row PG
    Kidney Int; 1975 Aug; 8(2):65-71. PubMed ID: 1099297
    [No Abstract]   [Full Text] [Related]  

  • 40. Chronic gouty nephropathy treated by long-term hemodialysis and allopurinol.
    Johnson WJ; O'Duffy JD
    Mayo Clin Proc; 1979 Sep; 54(9):618-20. PubMed ID: 470461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.